alzheimer's semaglutide evoke trial Novo Nordisk's results to be presented at CTAD 2025 Evaluating Semaglutide for Alzheimer's Disease

Patients should verify the current regulatory status and applicable compounding pathway directly with Eden and with a licensed healthcare professional before enrolling

If nausea persists beyond a week at any dose, discuss slowing your titration with your provider

This initial step allows our affiliated medical providers to evaluate your eligibility for prescription medications and tailor a treatment plan specifically for you

Ozempic (maximum dose 2.0 mg) is approved for type 2 diabetes, while Wegovy (maximum dose 2.4 mg) is approved for weight management

We offer competitive pricing and personalized care from an expert physician and staff